<DOC>
	<DOC>NCT01886469</DOC>
	<brief_summary>The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.</brief_summary>
	<brief_title>A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<criteria>Main Inclusion Criteria Male and female adolescents (1217 years; Stage 1) and children (611 years; Stage 2). Diagnosis of ADHD and confirmed on KiddieSchedule for Affective Disorders and Schizophrenia (KSADS). ADHD symptoms controlled on a stable dose of Vyvanse, Adderall XR and or Dexedrine. Provision of informed consent (from parent[s] or legal representative[s]) and assent (from subject) for patients. Main Exclusion Criteria Comorbid psychiatric diagnosis (e.g., psychosis, bipolar disorder). History of seizures or current diagnosis or family history of Tourette's disorder. Use of prescription drugs (except Vyvanse, Dexedrine or Adderall XR) the 14 days and overthecounter drugs (except birth control) the 30 days before the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>